Rallybio (RLYB) Operating Expenses (2020 - 2026)
Rallybio (RLYB) posted Operating Expenses of $8.9 million for Q1 2026, up 34.84% sequentially from $6.6 million in Q4 2025, and down 9.48% YoY from $9.9 million in Q1 2025.
Rallybio (RLYB) Operating Expenses (2020 - 2026) Analysis & Trends
Rallybio has reported Operating Expenses for 7 years, with the latest figure at $8.9 million in Q1 2026.
- Quarterly Operating Expenses fell 9.48% year-over-year to $8.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.0 million (down 35.61% YoY) and the FY2025 annual result came in at $33.9 million, down 44.51% from the prior year.
- Operating Expenses rose to $8.9 million in Q1 2026 per RLYB's latest filing, from $6.6 million in the prior quarter.
- Over five years, Operating Expenses peaked at $21.1 million in Q4 2023 and troughed at $6.6 million in Q4 2025.
- A 5-year average of $14.8 million and a median of $17.1 million in 2022 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2022 and 2025: Operating Expenses surged 88.96% in 2022, then slumped 50.06% in 2025.
- Over 5 years, Operating Expenses stood at $17.1 million in 2022, then increased by 23.53% to $21.1 million in 2023, then sank by 44.84% to $11.6 million in 2024, then slumped by 43.04% to $6.6 million in 2025, then soared by 34.84% to $8.9 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $8.9 million, $6.6 million, and $7.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Rallybio | 95.20 Mn | 95.20 Mn | - | 5.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.65 Mn |
| Mar 31, 2026 | 8.95 Mn |
| Dec 31, 2025 | 6.63 Mn |
| Sep 30, 2025 | 7.14 Mn |
| Jun 30, 2025 | 10.27 Mn |
| Mar 31, 2025 | 9.88 Mn |
| Dec 31, 2024 | 11.65 Mn |
| Sep 30, 2024 | 12.37 Mn |
| Jun 30, 2024 | 17.33 Mn |
| Mar 31, 2024 | 19.79 Mn |
| Dec 31, 2023 | 21.11 Mn |
| Sep 30, 2023 | 19.36 Mn |
| Jun 30, 2023 | 20.08 Mn |
| Mar 31, 2023 | 18.37 Mn |
| Dec 31, 2022 | 17.09 Mn |
| Sep 30, 2022 | 18.86 Mn |
| Jun 30, 2022 | 17.62 Mn |
| Mar 31, 2022 | 14.32 Mn |
| Dec 31, 2021 | 12.31 Mn |
| Sep 30, 2021 | 9.98 Mn |